Abstract

A series of novel lipophilic platinum(II) compounds containing salicylate derivatives as the leaving group have been designed, synthesised and characterised. Most of the platinum compounds exhibit high solubility and have a partition coefficient suited to liposomal encapsulation. Some of the compounds are more pharmacologically active and/or less toxic than carboplatin and oxaliplatin. The liposomal formulation of the most promising compound has been successfully prepared with long stability and high encapsulation rate, showing great potential to be developed as a new tumour-target drug.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call